<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="50659">Dronedarone</z:chebi> restores sinus rhythm and reduces hospitalization or <z:hpo ids='HP_0011420'>death</z:hpo> in intermittent <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular antiarrhythmic effects </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that <z:chebi fb="0" ids="50659">dronedarone</z:chebi> would reduce major vascular events in high-risk <z:hpo ids='HP_0004754'>permanent atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We assigned patients who were at least 65 years of age with at least a 6-month history of <z:hpo ids='HP_0004754'>permanent atrial fibrillation</z:hpo> and risk factors for major vascular events to receive <z:chebi fb="0" ids="50659">dronedarone</z:chebi> or placebo </plain></SENT>
<SENT sid="4" pm="."><plain>The first coprimary outcome was <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, <z:mpath ids='MPATH_118'>systemic embolism</z:mpath>, or <z:hpo ids='HP_0011420'>death</z:hpo> from cardiovascular causes </plain></SENT>
<SENT sid="5" pm="."><plain>The second coprimary outcome was unplanned hospitalization for a cardiovascular cause or <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: After the enrollment of 3236 patients, the study was stopped for safety reasons </plain></SENT>
<SENT sid="7" pm="."><plain>The first coprimary outcome occurred in 43 patients receiving <z:chebi fb="0" ids="50659">dronedarone</z:chebi> and 19 receiving placebo (hazard ratio, 2.29; 95% confidence interval [CI], 1.34 to 3.94; P=0.002) </plain></SENT>
<SENT sid="8" pm="."><plain>There were 21 <z:hpo ids='HP_0011420'>deaths</z:hpo> from cardiovascular causes in the <z:chebi fb="0" ids="50659">dronedarone</z:chebi> group and 10 in the placebo group (hazard ratio, 2.11; 95% CI, 1.00 to 4.49; P=0.046), including <z:hpo ids='HP_0011420'>death</z:hpo> from <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> in 13 patients and 4 patients, respectively (hazard ratio, 3.26; 95% CI, 1.06 to 10.00; P=0.03) </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> occurred in 23 patients in the <z:chebi fb="0" ids="50659">dronedarone</z:chebi> group and 10 in the placebo group (hazard ratio, 2.32; 95% CI, 1.11 to 4.88; P=0.02) </plain></SENT>
<SENT sid="10" pm="."><plain>Hospitalization for <z:hpo ids='HP_0001635'>heart failure</z:hpo> occurred in 43 patients in the <z:chebi fb="0" ids="50659">dronedarone</z:chebi> group and 24 in the placebo group (hazard ratio, 1.81; 95% CI, 1.10 to 2.99; P=0.02) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="50659">Dronedarone</z:chebi> increased rates of <z:hpo ids='HP_0001635'>heart failure</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo>, and <z:hpo ids='HP_0011420'>death</z:hpo> from cardiovascular causes in patients with <z:hpo ids='HP_0004754'>permanent atrial fibrillation</z:hpo> who were at risk for major vascular events </plain></SENT>
<SENT sid="12" pm="."><plain>Our data show that this drug should not be used in such patients </plain></SENT>
<SENT sid="13" pm="."><plain>(Funded by Sanofi-Aventis; PALLAS ClinicalTrials.gov number, NCT01151137.) </plain></SENT>
</text></document>